Table 1 Demographic and baseline characteristics of health outcomes population and all randomized patients (efficacy population)
From: Health status in the TORCH study of COPD: treatment efficacy and other determinants of change
Variable | Placebo (n = 1231) | SAL (n = 1232) | FP (n = 1248) | SFC (n = 1240) | Total HO population (n = 4951) | Total population (n = 6112) |
|---|---|---|---|---|---|---|
Age at enrollment (years) | 65.0 (8.2) | 65.2 (8.2) | 65.0 (8.5) | 65.0 (8.3) | 65.1 (8.3) | 65.0 (8.3) |
Male gender (%) | 921 (75) | 926 (75) | 923 (74) | 912 (74) | 3682 (74) | 4631 (76) |
BMI (kg/m2) | 25.8 (5.2) | 25.7 (5.1) | 25.6 (5.2) | 25.6 (5.3) | 25.7 (5.2) | 25.4 (5.18) |
Geographical region (%) | ||||||
USA | 342 (27.8) | 344 (27.9) | 348 (27.9) | 345 (27.8) | 1379 (27.9) | 1388 (22.7) |
Asia-Pacific | 89 (7.2) | 93 (7.5) | 95 (7.6) | 93 (7.5) | 370 (7.5) | 758 (12.4) |
Eastern Europe | 185 (15) | 186 (15.1) | 185 (14.8) | 184 (14.8) | 740 (14.9) | 1154 (18.9) |
Western Europe | 410 (33.3) | 405 (32.9) | 413 (33.1) | 409 (33) | 1637 (33.1) | 1908 (31.2) |
Other | 205 (16.7) | 204 (16.6) | 207 (16.6) | 209 (16.9) | 825 (16.7) | 935 (15.3) |
Current smoker (%) | 538 (44) | 536 (44) | 543 (44) | 539 (43) | 2156 (44) | 2630 (43) |
Pack-years smoked | 49.5 (27.5) | 50.6 (28.6) | 50.0 (28.8) | 47.7 (26.6) | 49.4 (27.9) | 48.5 (27.4) |
Post-bronchodilator FEV1 (l)* | 1.24 (0.42) | 1.21 (0.40) | 1.22 (0.42) | 1.24 (0.43) | 1.23 (0.42) | 1.22 (0.42) |
Post-bronchodilator FEV1 (% predicted*) | 44.5 (12.3) | 43.7 (12.4) | 44.3 (12.3) | 44.6 (12.3) | 44.3 (12.3) | 44.0 (12.4) |
Reversibility (% predicted FEV1)* | 3.7 (3.8) | 3.7 (4.0) | 3.6 (3.7) | 3.7 (3.6) | 3.7 (3.8) | 3.7 (3.7) |
Pre-bronchodilator FEV1/FVC ratio* | 48.4 (11.0) | 48.6 (11.0) | 48.1 (10.8) | 48.1 (10.8) | 48.3 (10.9) | 48.6 (10.8) |
Baseline SGRQ total score | 49.0 (17.4) | 49.9 (16.6) | 49.5 (17.1) | 48.9 (17.4) | 49.3 (17.1) | - |